Αρχική World News Using Artificial Intelligence to Classify Lung Cancer Types, Predict Mutations

Using Artificial Intelligence to Classify Lung Cancer Types, Predict Mutations

October 10, 2018, by NCI Staff

The AI-driven computer program analyzes tissue by creating a map of thousands of tiles. The map on the right shows squamous cell carcinoma (red), lung squamous cell carcinoma (blue), and normal lung tissue (gray).

Credit: NYU School of Medicine

Researchers have trained a computer program to read slides of tissue samples to diagnose two of the most common types of lung cancer with 97% accuracy. The program also learned to detect cancer-related genetic mutations in the samples just by analyzing the images of cancer tissue.

In a process known as machine learning, the computer program scanned images of tissue slices and developed the ability to differentiate normal lung tissue from the two most common forms of lung cancer, adenocarcinomas, which make up about 40% of lung cancers, and squamous cell carcinomas, which make up about 25% to 30% of lung cancers. Even experienced pathologists can struggle to distinguish these two types of lung cancer, which arise from different types of cells and require very different treatment regimens.

To train the computer program, researchers specializing in machine learning used a deep learning method originally developed and published by Google. The program uses artificial intelligence (AI) to teach itself to get better at a task—in this case, classifying lung cancer specimens—without being told exactly how.

The program was trained using more than 1,600 histopathology slides of lung specimens made publicly available by The Cancer Genome Atlas (TCGA). The study, led by researchers at New York University’s Langone Medical Center and published September 17 in Nature Medicine, represents a large improvement in the accuracy of computational methods to diagnose lung cancer; the second most accurate computational method has an accuracy rate of 83%.

Images as Data and a Public Resource

TCGA made histopathology images of tumor specimens available as a quality control measure for researchers studying the genetic sequence data collected in the project. The images “were required to make sure that the quality and identity of the tissue were correct,” said Jean C. Zenklusen, Ph.D., the director of TCGA at NCI. As an incidental benefit, Dr. Zenklusen said, the images themselves now serve as a resource for analysis.

The images made available by TCGA are large and high resolution, so the researchers at NYU divided each image into thousands of tiles, or “patches,” in a grid for the computer program to analyze individually for visual cues that could be linked to the sample’s classification. “We had about 500 patients per [lung cancer] subtype, but thousands of patches per image, so we had nearly one million patches in the end to train the model,” said Narges Razavian, Ph.D., a machine learning and AI researcher at NYU Langone, who helped lead the study.

The accuracy with which the program learned to distinguish adenocarcinoma from squamous cell carcinoma and normal lung cells was about equal to that of experienced pathologists, but the analysis can be done much faster; the program was able to reach a conclusion in a matter of seconds rather than the minutes a pathologist would need.

The program also correctly classified 45 of 54 images that at least one of three pathologists participating in the study misclassified, suggesting that AI could offer a useful second opinion, the researchers wrote.

The program was tested on an independent set of lung cancer specimens—both frozen and freshly collected—from NYU to verify that it worked on a completely separate collection of samples.

The samples from TCGA were almost entirely tumor tissue. In this validation set, however, the samples often included other components, such as blood clots and dead tissue, “making the classification task more challenging” for the program, the researchers reported. 

In response, they reworked the program to have it focus on the parts of the tissue samples that were largely tumor (as identified by a pathologist). With that change, the method’s accuracy averaged more than 90%, which they described as “very encouraging.”

AI’s Role in Treatment and Research

Because of the computer program’s speed and accuracy, the research team suggested the tool could be used during surgery, for example, to help verify that a biopsy is of sufficient quality to make a diagnosis or to inform a surgeon that another sample is needed.

In addition to showing that AI can be used to make a quick and accurate diagnosis, the research project showed that AI could be trained to predict the presence of six of the most common genetic mutations in lung cancer adenocarcinoma, with an accuracy ranging from 64% to 86%, depending on the gene.

“That is very exciting scientifically,” Dr. Razavian said.

Currently, the only way humans can detect genetic mutations is by DNA sequencing, which can take up to 2 weeks.

“Lung cancer is usually detected late in the progression of the disease, so waiting 2 weeks to start any treatment is bad for the patient,” Dr. Razavian noted.

Many medical teams will start treatment and then adjust the medication used based on genetic test results. “What we show is that, with this program, you could start a treatment that is more likely to be the right one immediately,” Dr. Razavian said.

The program is a “black box,” in that its decisions are the result of thousands of interconnected small steps, not easy to summarize. The researchers can’t visualize exactly what the program detects in an image to predict the presence of genetic mutations, but the program can serve as “a lens that shows patterns that are hard to notice with the eye,” Dr. Razavian said.

She and her colleagues are using the program to research how genetic mutations affect the structures of cells and tissues. To approach this problem, they are using automated methods that modify the images to figure out what visual elements most influence the program’s ability to perceive mutations.

“The strengths of the study,” said Paula Jacobs, Ph.D., the associate director of NCI’s Cancer Imaging Program, “are the careful selection of the clinical problem to be addressed,” how the program was trained, and the fact that the results were verified using an independent set of lung cancer specimens.

Michael Snyder, Ph.D., chair of genetics at Stanford University, sees AI as the future of diagnosis. “I think we need to shift to using machine learning rather than rely on pathologists alone to do all the work,” he said. “Algorithms won’t replace pathologists, but they will assist them in making classifications. They will reduce the errors that pathologists would otherwise make.”

The code developed for the project is available for other researchers to use for other diagnostic applications. The NYU team has already started applying the code to learn to diagnose kidney, breast, and other cancers.



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

Mother Spent 14 Weeks Battling Breast Cancer Alone During COVID-19 Lockdown

Battling cancer is difficult for anyone, but it’s even harder when you have to do it alone. That’s what happened to Samantha Currie. Samantha, 27,...

ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and Bladder Cancer

The 2020 European Society for Medical Oncology (ESMO) Virtual Congress was held online from September 19 to September 21. In this podcast, Neeraj Agarwal,...

The UK Government’s spending review: Time to invest in the future of cancer care

This autumn, the chancellor Rishi Sunak will go to Parliament and set out the UK Government’s spending priorities in the Comprehensive Spending Review...

Nivolumab Improves Survival for Some Patients with Advanced Stomach Cancer

October 20, 2020, by NCI Staff Some people with advanced stomach cancers may live longer if they are initially treated with nivolumab (Opdivo) and chemotherapy. Credit: National Cancer Institute Some...

Sugar and cancer – what you need to know

This post was first published in 2017 but has been reviewed and updated in October 2020. There’s a lot of confusing information and advice out...

FDA Extends Approval of Pembrolizumab for Classical Hodgkin Lymphoma

On 14 October 2020, the US Food and Drug Administration (FDA) extended the approval of pembrolizumab (KEYTRUDA®, Merck Sharp & Dohme Corp.) for the...